← Eichor
Study identifier: NCT06875986 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

REXULTI Drug General Use-results Survey (Excessive Motor Activity or Physically/Verbally Aggressive Behavior Due to Rapid Changes in Mood, Irritability, and/or Outbursts Associated With Dementia Due to Alzheimer's Disease)

Condition: Alzheimer Disease  ·  Sponsor: Otsuka Pharmaceutical Co., Ltd.

PhaseN/A
Planned participants200
Who can joinAll sexes, 15 Years to no upper limit
Healthy volunteersNo

About this study

The purpose of this study is to evaluate safety of REXULTI in patients under daily clinical settings. In addition, information on efficacy will be collected.

This description comes directly from the study's public registry record.

Talk to the study team

Pharmacovigilance Department Otsuka Pharmaceutical Co., Ltd  ·  +81-6-6943-7722  ·  komaniwa.satoshi@otsuka.jp

Always discuss trial participation with your own doctor first.

Locations (1)

Pharmacovigilance DepartmentOsaka, Osaka, JapanRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06875986